Kura Oncology Q3 net loss $54.4M; cash $455.3M; ziftomenib data expected early 2025

Kura Oncology, Inc.

2024-Q3 EPS reported -$1.80

Net loss $54.4M in Q3 2024 vs $38.6M in Q3 2023; R&D expenses $41.7M.
Cash, cash equivalents and investments $455.3M as of Sep 30, 2024; runway into 2027.
Topline results from registration-directed ziftomenib trial in R/R NPM1-mutant AML expected early 2025.
Phase 1b expansion study of ziftomenib enrolling at 600 mg; 45 patients enrolled since Aug 2024.
First patient dosed in KO-2806 + adagrasib in KRAS G12C NSCLC; GIST proof-of-concept study planned 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.